Atlas Venture Fund XI, L.P. 13D and 13G filings for Day One Biopharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 4,869,681 5.500% |
-1,178,137 (-19.48%) |
Filing |
| 2024-02-09 4:08 pm Purchase |
2023-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 6,047,818 6.900% |
39,284 (+0.65%) |
Filing |
| 2023-02-14 4:23 pm Sale |
2022-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 6,008,534 8.200% |
-1,201,708 (-16.67%) |
Filing |
| 2022-02-11 5:03 pm Purchase |
2021-06-01 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 7,210,242 11.600% |
7,210,242 (New Position) |
Filing |